It is intended to provide a transgenic nonhuman mammal well representing
the pathologic conditions of human rheumatoid arthritis. A transgenic
nonhuman mammal is obtained by transferring a foreign DNA, wherein a DNA
selected from the group consisting of an MHC class II transcriptional
activator gene, the activity domain of an MHC class II transcriptional
activator gene and a variant of an MHC class II transcriptional activator
gene is provided under the control of a type II collagen promoter, into a
cell at the early stage of development.